Back to top

MaxCyte (MXCT) Receives a Buy from Craig-Hallum

Craig-Hallum analyst Matt Hewitt maintained a Buy rating on MaxCyte on July 2. The company’s shares closed last Thursday at $1.22. Hewitt covers th...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

MaxCyte, Inc. (MXCT)